Tirofiban, a GP IIb/IIIa inhibitor, improved functional outcomes independent of premedication in patients with stroke due to acute extracranial carotid lesions and emergency CAS with lower rates of SICH (52). This evidence concerns the gene ITGA2B and stroke disorder.